TAB3 promotes human esophageal squamous cell carcinoma proliferation and invasion via the NF‑κB pathway

Zhao,Jiyi; Gai,Ling; Gao,Yi; Xia,Wenkai; Shen,Dong; Lin,Qingfeng; Mao,Weidong; Wang,Fangjun; Liu,Pengfei; Chen,Jie

doi:10.3892/or.2018.6686

TAB3 promotes human esophageal squamous cell carcinoma proliferation and invasion via the NF‑κB pathway

Authors:
- Jiyi Zhao
- Ling Gai
- Yi Gao
- Wenkai Xia
- Dong Shen
- Qingfeng Lin
- Weidong Mao
- Fangjun Wang
- Pengfei Liu
- Jie Chen
View Affiliations

Affiliations: Department of Gastroenterology, The Jiangyin Clinical College of Xuzhou Medical University, Wuxi, Jiangsu 214400, P.R. China, Department of Oncology, The Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Gastroenterology, The Jiangyin Clinical College of Xuzhou Medical University, Wuxi, Jiangsu 214400, P.R. China, Department of Nephrology, The Jiangyin Clinical College of Xuzhou Medical University, Wuxi, Jiangsu 214400, P.R. China, Department of Oncology, The Jiangyin Clinical College of Xuzhou Medical University, Wuxi, Jiangsu 214400, P.R. China, Department of Oncology, The Jiangyin Clinical College of Xuzhou Medical University, Wuxi, Jiangsu 214400, P.R. China
Published online on: September 6, 2018 https://doi.org/10.3892/or.2018.6686
Pages: 2876-2885

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal squamous cell carcinoma (ESCC) has become one of the most common causes of cancer‑associated mortality worldwide. Transforming growth factor‑activated kinase (TAK1)‑binding protein 3 (TAB3) is essential for activation of the NF (NF)‑κB pathway in response to TAK1 activation. The NF‑κB pathway serves important roles in tumor cell proliferation and migration; however, the clinical relevance of TAB3 and its biological function in ESCC progression remain elusive. The present study investigated the expression and function of TAB3 in ESCC tissues, and its association with the clinical prognosis of patients. The results demonstrated that TAB3 expression was significantly increased in human ESCC cell lines and tissue samples, and the expression of TAB3 was associated with ESCC lymph node metastasis, T stage, pathological grade and Ki‑67 expression in 80 ESCC samples, as determined by immunohistochemistry. Patients with ESCC and high TAB3 expression exhibited worse overall survival. Furthermore, knockdown of TAB3 by small interfering RNA inhibited the proliferation of ESCC cells, and reduced the migration and invasion of ESCC cells. In addition, knockdown of TAB3 decreased the expression of the NF‑κB pathway in TE‑1 cells. Taken together, these results demonstrated that TAB3 may be a promising therapeutic target for the treatment of ESCC.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
3	Yano T, Muto M, Minashi K, Iwasaki J, Kojima T, Fuse N, Doi T, Kaneko K and Ohtsu A: Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: A phase II study. Int J Cancer. 131:1228–1234. 2012. View Article : Google Scholar : PubMed/NCBI
4	Zhang L, Wu YD, Li P, Tu J, Niu YL, Xu CM and Zhang ST: Effects of cyclooxygenase-2 on human esophageal squamous cell carcinoma. World J Gastroenterol. 17:4572–4580. 2011. View Article : Google Scholar : PubMed/NCBI
5	Lagergren J, Smyth E, Cunningham D and Lagergren P: Oesophageal cancer. Lancet. 390:2383–2396. 2017. View Article : Google Scholar : PubMed/NCBI
6	Rustgi AK and El-Serag HB: Esophageal carcinoma. N Engl J Med. 371:2499–2509. 2014. View Article : Google Scholar : PubMed/NCBI
7	Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
8	Takaesu G, Kishida S, Hiyama A, Yamaguchi K, Shibuya H, Irie K, Ninomiya-Tsuji J and Matsumoto K: TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell. 5:649–658. 2000. View Article : Google Scholar : PubMed/NCBI
9	Besse A, Lamothe B, Campos AD, Webster WK, Maddineni U, Lin SC, Wu H and Darnay BG: TAK1-dependent signaling requires functional interaction with TAB2/TAB3. J Biol Chem. 282:3918–3928. 2007. View Article : Google Scholar : PubMed/NCBI
10	Hu Y, Liu JP, Zhu Y and Lu NH: The importance of toll-like receptors in NF-κB signaling pathway activation by helicobacter pylori infection and the regulators of this response. Helicobacter. 21:428–440. 2016. View Article : Google Scholar : PubMed/NCBI
11	Chen J, Gu J, Feng J, Liu Y, Xue Q, Ni T, Wang Z, Jia L, Mao G and Ji L: TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway. Tumour Biol. 37:3851–3861. 2016. View Article : Google Scholar : PubMed/NCBI
12	Tao T, He Z, Shao Z and Lu H: TAB3 O-GlcNAcylation promotes metastasis of triple negative breast cancer. Oncotarget. 7:22807–22818. 2016. View Article : Google Scholar : PubMed/NCBI
13	Chen Y, Wang X, Duan C, Chen J, Su M, Jin Y, Deng Y, Wang D, Chen C, Zhou L, et al: Loss of TAB3 expression by shRNA exhibits suppressive bioactivity and increased chemical sensitivity of ovarian cancer cell lines via the NF-κB pathway. Cell Prolif. 49:657–668. 2016. View Article : Google Scholar : PubMed/NCBI
14	Sobin LH, Gospodarowicz MK and Wittekind C: TNM classification of malignant tumours. John Wiley & Sons; 2011
15	Roh YS, Song J and Seki E: TAK1 regulates hepatic cell survival and carcinogenesis. J Gastroenterol. 49:185–194. 2014. View Article : Google Scholar : PubMed/NCBI
16	Luo C, Yuan R, Chen L, Zhou W, Shen W, Qiu Y and Shao J, Yan J and Shao J: TAB3 upregulates Survivin expression to promote colorectal cancer invasion and metastasis by binding to the TAK1-TRAF6 complex. Oncotarget. 8:106565–106576. 2017. View Article : Google Scholar : PubMed/NCBI
17	Malumbres M and Carnero A: Cell cycle deregulation: A common motif in cancer. Prog Cell Cycle Res. 5:5–18. 2003.PubMed/NCBI
18	Boonstra J and Moes MJ: Signal transduction and actin in the regulation of G1-phase progression. Crit Rev Eukaryot Gene Expr. 15:255–276. 2005. View Article : Google Scholar : PubMed/NCBI
19	Hulleman E and Boonstra J: Regulation of G1 phase progression by growth factors and the extracellular matrix. Cell Mol Life Sci. 58:80–93. 2001. View Article : Google Scholar : PubMed/NCBI
20	Tashima Y, Hamada H, Okamoto M and Hanai T: Prediction of key factor controlling G1/S phase in the mammalian cell cycle using system analysis. J Biosci Bioeng. 106:368–374. 2008. View Article : Google Scholar : PubMed/NCBI
21	Gan J, Ke X, Jiang J, Dong H, Yao Z, Lin Y, Lin W, Wu X, Yan S, Zhuang Y, et al: Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-kappaB signaling. Proc Natl Acad Sci USA. 113:14745–14750. 2016. View Article : Google Scholar : PubMed/NCBI
22	Jung JU, Ravi S, Lee DW, McFadden K, Kamradt ML, Toussaint LG and Sitcheran R: NIK/MAP3K14 regulates mitochondrial dynamics and trafficking to promote cell invasion. Curr Biol. 26:3288–3302. 2016. View Article : Google Scholar : PubMed/NCBI
23	Gan X, Chen B, Shen Z, Liu Y, Li H, Xie X, Xu X, Li H, Huang Z and Chen J: High GPX1 expression promotes esophageal squamous cell carcinoma invasion, migration, proliferation and cisplatin-resistance but can be reduced by vitamin D. Int J Clin Exp Med. 7:2530–2540. 2014.PubMed/NCBI
24	Han Y, Guo XH, Zheng QF, Zhu YL, Fan YY and Zhang XY: Down-regulation of platelet-derived growth factor-D expression blockades NF-κB pathway to inhibit cell proliferation and invasion as well as induce apoptosis in esophageal squamous cell carcinoma. Mol Biol Rep. 40:2473–2483. 2013. View Article : Google Scholar : PubMed/NCBI
25	Gao S, Sun Y, Zhang X, Hu L, Liu Y, Chua CY, Phillips LM, Ren H, Fleming JB, Wang H, et al: IGFBP2 activates the NF-κB pathway to drive epithelial-mesenchymal transition and invasive character in pancreatic ductal adenocarcinoma. Cancer Res. 76:6543–6554. 2016. View Article : Google Scholar : PubMed/NCBI
26	Pires BR, Mencalha AL, Ferreira GM, de Souza WF, Morgado-Díaz JA, Maia AM, Corrêa S and Abdelhay ES: NF-kappaB is involved in the regulation of EMT genes in breast cancer cells. PLoS One. 12:e01696222017. View Article : Google Scholar : PubMed/NCBI
27	Shin WS, Hong Y, Lee HW and Lee ST: Catalytically defective receptor protein tyrosine kinase PTK7 enhances invasive phenotype by inducing MMP-9 through activation of AP-1 and NF-κB in esophageal squamous cell carcinoma cells. Oncotarget. 7:73242–73256. 2016. View Article : Google Scholar : PubMed/NCBI
28	Zhou J, Zheng S, Liu T, Liu Q, Chen Y, Tan D, Ma R and Lu X: MCP2 activates NF-κB signaling pathway promoting the migration and invasion of ESCC cells. Cell Biol Int. 42:365–372. 2018. View Article : Google Scholar : PubMed/NCBI
29	Jin G, Klika A, Callahan M, Faga B, Danzig J, Jiang Z, Li X, Stark GR, Harrington J and Sherf B: Identification of a human NF-kappaB-activating protein, TAB3. Proc Natl Acad Sci USA. 101:2028–2033. 2004. View Article : Google Scholar : PubMed/NCBI